Literature DB >> 35507174

Reprogramming Mouse Oviduct Epithelial Cells Using In Vivo Electroporation and CRISPR/Cas9-Mediated Genetic Manipulation.

Matthew J Ford1, Yojiro Yamanaka2.   

Abstract

Advances in gene editing tools such as CRISPR/Cas9 have made precise in vivo gene editing possible, opening up avenues of research into somatic cell reprograming to study adult stem cells, homeostasis, and malignant transformation. Here we describe a method for CRISPR/Cas9 mediated in vivo gene editing, in combination with Cre-based lineage tracing via electroporation in the mouse oviduct. This method facilitates the delivery of multiple plasmids into oviduct epithelial cells, sufficient for studying homeostasis and generation of high-grade serous ovarian cancer (HGSOC) models.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR; Fallopian tube; HGSOC; Homeostasis; In vivo gene editing; Ovarian cancer; Oviduct

Mesh:

Year:  2022        PMID: 35507174     DOI: 10.1007/978-1-0716-1979-7_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Long-term organoid culture reveals enrichment of organoid-forming epithelial cells in the fimbrial portion of mouse fallopian tube.

Authors:  Ying Xie; Eun-Sil Park; Dongxi Xiang; Zhe Li
Journal:  Stem Cell Res       Date:  2018-08-25       Impact factor: 2.020

Review 2.  Lineage Tracing: Computational Reconstruction Goes Beyond the Limit of Imaging.

Authors:  Szu-Hsien Sam Wu; Ji-Hyun Lee; Bon-Kyoung Koo
Journal:  Mol Cells       Date:  2019-02-13       Impact factor: 5.034

3.  A Cell/Cilia Cycle Biosensor for Single-Cell Kinetics Reveals Persistence of Cilia after G1/S Transition Is a General Property in Cells and Mice.

Authors:  Matthew J Ford; Patricia L Yeyati; Girish R Mali; Margaret A Keighren; Scott H Waddell; Heidi K Mjoseng; Adam T Douglas; Emma A Hall; Asako Sakaue-Sawano; Atsushi Miyawaki; Richard R Meehan; Luke Boulter; Ian J Jackson; Pleasantine Mill; Richard L Mort
Journal:  Dev Cell       Date:  2018-11-19       Impact factor: 12.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.